Evotec expands collaboration with Intermune
Evotec has signed a second agreement that gives InterMune access to its proprietary fragment-based drug discovery technology.
Evotec has signed a second agreement that gives InterMune access to its proprietary fragment-based drug discovery technology.
The collaboration is the second of its kind between the two companies, which, this time aims to further InterMune's Hepatitis C drug discovery and development programme.
Evotec specialises in novel small molecule drug development and can support InterMune in areas of computational chemistry, protein production, X-ray crystallography and ADMET.
Evotec started collaborations with InterMune in early 2007, looking at its fragment-based drug discovery platform EVOlution in combination with its ultra-high-throughput screening (uHTS) technologies to InterMune's targets.
The financial terms include a technology access fee for access to Evotec's fragment-based drug discovery platform, EVOlutionTM, plus ongoing research funding.
"With the support of Evotec, InterMune has made considerable progress in their Hepatitis C drug discovery and development program. We are pleased that InterMune saw the value in our proprietary fragment-based drug discovery technology and that it has contributed to the success to their research efforts," said Dr Mark Ashton, executive vice president business development services at Evotec.